Cheng Sohanya Roshan's Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed Mar 2, 2023
- Accession no.
- 0001209191-23-014861
- Filed
- Mar 2, 2023
- Trade date
- Feb 28-Mar 1, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $34.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng Sohanya RoshanCIK 0001865796 | Officer (EVP & Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2023 | Common Stock | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 221,926 | Direct | |
| Mar 1, 2023 | Common Stock | SSaleDisposed | −11,239 | $3.03 | −$34,054.17 | 210,687 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.